Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease

Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease

Lay Summary Despite a high approval rate, there were unnecessary delays in therapy due to prior authorizations. This study identified the impact of type of IBD, FDA-labeled indication, and dose escalations on approvals.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Inflammatory bowel diseases 2023-10, Vol.29 (10), p.1658-1661
Hauptverfasser: Choi, David K, Cohen, Nathaniel A, Choden, Tenzin, Cohen, Russell D, Rubin, David T
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1661
container_issue 10
container_start_page 1658
container_title Inflammatory bowel diseases
container_volume 29
creator Choi, David K
Cohen, Nathaniel A
Choden, Tenzin
Cohen, Russell D
Rubin, David T
description Lay Summary Despite a high approval rate, there were unnecessary delays in therapy due to prior authorizations. This study identified the impact of type of IBD, FDA-labeled indication, and dose escalations on approvals.
doi_str_mv 10.1093/ibd/izad012
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2771089862</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ibd/izad012</oup_id><sourcerecordid>2771089862</sourcerecordid><originalsourceid>FETCH-LOGICAL-c320t-e0096dd268cbc4fbdc748ba9ddd0a9fe2c40b525e2eb83041dcf6c8d6198086b3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlZP3iUnEWRtkt3uJsfa-lEo6KHicckmszSyu6lJFqm_3pRWjzKHGWYe3oEHoUtK7igR6dhUemy-pSaUHaEhnaR5kvEsO44zKXhChOADdOb9ByEsljhFgzQv6ISJbIj6OTRy67Hp8GoNTm62eOq9VUYG0PjdhDWe9c5BF_CrM9bhaR_W1sV_wdgu7qwC73EdL2ENeOVAhnZH2xovurqRbSuDdVt8b7-gwXPjQXo4Rye1bDxcHPoIvT0-rGbPyfLlaTGbLhOVMhISIETkWrOcq0pldaVVkfFKCq01kaIGpjJSTdgEGFQ8JRnVqs4V1zkVnPC8SkfoZp-7cfazBx_K1ngFTSM7sL0vWVFQwgXPWURv96hy1nsHdblxppVuW1JS7jyX0XN58Bzpq0NwX7Wg_9hfsRG43gO23_yb9APWd4lN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2771089862</pqid></control><display><type>article</type><title>Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Choi, David K ; Cohen, Nathaniel A ; Choden, Tenzin ; Cohen, Russell D ; Rubin, David T</creator><creatorcontrib>Choi, David K ; Cohen, Nathaniel A ; Choden, Tenzin ; Cohen, Russell D ; Rubin, David T</creatorcontrib><description>Lay Summary Despite a high approval rate, there were unnecessary delays in therapy due to prior authorizations. This study identified the impact of type of IBD, FDA-labeled indication, and dose escalations on approvals.</description><identifier>ISSN: 1078-0998</identifier><identifier>EISSN: 1536-4844</identifier><identifier>DOI: 10.1093/ibd/izad012</identifier><identifier>PMID: 36715294</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>Inflammatory bowel diseases, 2023-10, Vol.29 (10), p.1658-1661</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of Crohn’s &amp; Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c320t-e0096dd268cbc4fbdc748ba9ddd0a9fe2c40b525e2eb83041dcf6c8d6198086b3</citedby><cites>FETCH-LOGICAL-c320t-e0096dd268cbc4fbdc748ba9ddd0a9fe2c40b525e2eb83041dcf6c8d6198086b3</cites><orcidid>0000-0002-2453-1784</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1584,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36715294$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Choi, David K</creatorcontrib><creatorcontrib>Cohen, Nathaniel A</creatorcontrib><creatorcontrib>Choden, Tenzin</creatorcontrib><creatorcontrib>Cohen, Russell D</creatorcontrib><creatorcontrib>Rubin, David T</creatorcontrib><title>Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease</title><title>Inflammatory bowel diseases</title><addtitle>Inflamm Bowel Dis</addtitle><description>Lay Summary Despite a high approval rate, there were unnecessary delays in therapy due to prior authorizations. This study identified the impact of type of IBD, FDA-labeled indication, and dose escalations on approvals.</description><issn>1078-0998</issn><issn>1536-4844</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMotlZP3iUnEWRtkt3uJsfa-lEo6KHicckmszSyu6lJFqm_3pRWjzKHGWYe3oEHoUtK7igR6dhUemy-pSaUHaEhnaR5kvEsO44zKXhChOADdOb9ByEsljhFgzQv6ISJbIj6OTRy67Hp8GoNTm62eOq9VUYG0PjdhDWe9c5BF_CrM9bhaR_W1sV_wdgu7qwC73EdL2ENeOVAhnZH2xovurqRbSuDdVt8b7-gwXPjQXo4Rye1bDxcHPoIvT0-rGbPyfLlaTGbLhOVMhISIETkWrOcq0pldaVVkfFKCq01kaIGpjJSTdgEGFQ8JRnVqs4V1zkVnPC8SkfoZp-7cfazBx_K1ngFTSM7sL0vWVFQwgXPWURv96hy1nsHdblxppVuW1JS7jyX0XN58Bzpq0NwX7Wg_9hfsRG43gO23_yb9APWd4lN</recordid><startdate>20231003</startdate><enddate>20231003</enddate><creator>Choi, David K</creator><creator>Cohen, Nathaniel A</creator><creator>Choden, Tenzin</creator><creator>Cohen, Russell D</creator><creator>Rubin, David T</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2453-1784</orcidid></search><sort><creationdate>20231003</creationdate><title>Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease</title><author>Choi, David K ; Cohen, Nathaniel A ; Choden, Tenzin ; Cohen, Russell D ; Rubin, David T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c320t-e0096dd268cbc4fbdc748ba9ddd0a9fe2c40b525e2eb83041dcf6c8d6198086b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Choi, David K</creatorcontrib><creatorcontrib>Cohen, Nathaniel A</creatorcontrib><creatorcontrib>Choden, Tenzin</creatorcontrib><creatorcontrib>Cohen, Russell D</creatorcontrib><creatorcontrib>Rubin, David T</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Inflammatory bowel diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Choi, David K</au><au>Cohen, Nathaniel A</au><au>Choden, Tenzin</au><au>Cohen, Russell D</au><au>Rubin, David T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease</atitle><jtitle>Inflammatory bowel diseases</jtitle><addtitle>Inflamm Bowel Dis</addtitle><date>2023-10-03</date><risdate>2023</risdate><volume>29</volume><issue>10</issue><spage>1658</spage><epage>1661</epage><pages>1658-1661</pages><issn>1078-0998</issn><eissn>1536-4844</eissn><abstract>Lay Summary Despite a high approval rate, there were unnecessary delays in therapy due to prior authorizations. This study identified the impact of type of IBD, FDA-labeled indication, and dose escalations on approvals.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>36715294</pmid><doi>10.1093/ibd/izad012</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-2453-1784</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1078-0998
ispartof Inflammatory bowel diseases, 2023-10, Vol.29 (10), p.1658-1661
issn 1078-0998
1536-4844
language eng
recordid cdi_proquest_miscellaneous_2771089862
source Oxford University Press Journals All Titles (1996-Current)
title Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T23%3A56%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Delays%20in%20Therapy%20Associated%20With%20Current%20Prior%20Authorization%20Process%20for%20the%20Treatment%20of%20Inflammatory%20Bowel%20Disease&rft.jtitle=Inflammatory%20bowel%20diseases&rft.au=Choi,%20David%20K&rft.date=2023-10-03&rft.volume=29&rft.issue=10&rft.spage=1658&rft.epage=1661&rft.pages=1658-1661&rft.issn=1078-0998&rft.eissn=1536-4844&rft_id=info:doi/10.1093/ibd/izad012&rft_dat=%3Cproquest_cross%3E2771089862%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2771089862&rft_id=info:pmid/36715294&rft_oup_id=10.1093/ibd/izad012&rfr_iscdi=true